Counting the cost of public and philanthropic R&D funding: the case of olaparib.

ABSTRACT:

Background

Lack of transparency around manufacturing costs, who bears the bulk of research and development costs and how total costs relate to the pricing of products, continue to fuel debates. This paper considers the case of olaparib (Lynparza®), recently indicated for use among BRCA-mutant breast cancer patients, and estimates the extent of public and philanthropic R&D funding.

Methods

We know from previous work that attempting to ascertain the amount of public and philanthropic funding using purely bibliographic sources (i.e., authors' declarations of funding sources and amounts traced through funders) is limited. Since we knew that a publically funded research unit was pivotal in developing olaparib, we decided to supplement bibliographic data with a Freedom of Informat

SUBMITTER: Schmidt L 

PROVIDER: S-EPMC9379234 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature